Clinical Report: HHS Proposes Revisions to Labeling for Testosterone Replacement Therapy Products

Overview

The U.S. Department of Health and Human Services has proposed updates to the prescribing information for testosterone replacement therapy products based on new clinical data. Key changes include the removal of limitations regarding safety and effectiveness in age-related hypogonadism and updates to prostate cancer risk information.

Background

Testosterone replacement therapy (TRT) is commonly used to treat men with low testosterone levels. Recent clinical trials, including the TRAVERSE trial, have provided new evidence that may support broader use of TRT.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The proposed changes would remove the limitation of use for TRT in men with age-related hypogonadism.
• Updated information regarding prostate cancer risk will state that TRT is contraindicated only in men with metastatic prostate cancer.
• Current labeling warnings about benign prostatic hyperplasia will be revised based on new evidence.
• The TRAVERSE trial found no significant increase in major adverse cardiovascular events among men receiving TRT.
• Healthcare providers are advised to assess risk and monitor patients during TRT.

Clinical Implications

The proposed labeling changes provide guidance for healthcare providers regarding the use of TRT in men with low testosterone levels.

Conclusion

The proposed revisions to TRT labeling reflect updates to prescribing information based on the latest scientific evidence.

Related Resources & Content

1. FDA, FDA, 2025 -- HHS Proposes Revisions to Labeling for Testosterone Replacement Therapy Products
2. conexiant — FDA Signals New Testosterone Pathway
3. the asco post — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
4. conexiant — FDA Approves HRT Label Changes
5. the asco post — ASCO Statement: HHS Revision of Black Box Warning for Hormone Replacement Therapy and its Implications for Cancer Care
6. FDA Signals New Testosterone Pathway
7. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
8. FDA Approves HRT Label Changes
9. ASCO Statement: HHS Revision of Black Box Warning for Hormone Replacement Therapy and its Implications for Cancer Care
10. FDA issues class-wide labeling changes for testosterone products | FDA
11. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic
12. Cardiovascular Safety of Testosterone-Replacement Therapy - PubMed